5/24
06:15 am
eprx
Eupraxia Pharmaceuticals expands trial of eosinophilic esophagitis therapy [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals expands trial of eosinophilic esophagitis therapy [Yahoo! Finance]
5/23
05:03 pm
eprx
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Yahoo! Finance]
5/23
05:00 pm
eprx
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Neutral
Report
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
5/23
06:02 am
eprx
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) was upgraded by analysts at Raymond James to a "strong-buy" rating.
Medium
Report
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) was upgraded by analysts at Raymond James to a "strong-buy" rating.
5/22
07:00 am
eprx
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
High
Report
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
5/21
05:05 pm
eprx
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Yahoo! Finance]
High
Report
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Yahoo! Finance]
5/21
05:00 pm
eprx
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Low
Report
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
5/14
07:00 am
eprx
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
Low
Report
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
5/8
05:07 pm
eprx
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/8
05:03 pm
eprx
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/2
07:13 am
eprx
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board [Yahoo! Finance]
Medium
Report
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board [Yahoo! Finance]
5/2
07:00 am
eprx
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
Medium
Report
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
4/11
07:06 am
eprx
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 [Yahoo! Finance]
Medium
Report
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 [Yahoo! Finance]
4/11
07:00 am
eprx
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
Medium
Report
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
4/8
07:00 am
eprx
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
High
Report
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference